Keyphrases
Chronic Migraine
100%
Single Center
100%
Prospective Observational Study
100%
Long-term Safety
100%
Long-term Efficacy
100%
Erenumab
100%
Monthly Migraine Days
83%
Adverse Events
33%
Adult Patients
33%
Clinical Trials
33%
Denmark
16%
Treatment Duration
16%
Outpatient Clinic
16%
Treatment Discontinuation
16%
Number of Patients
16%
Tolerability
16%
Patient-completed
16%
Headache Centres
16%
Preventive Treatment
16%
Migraine Prevention
16%
Constipation
16%
Monoclonal Antibody
16%
One Dose
16%
Observation Study
16%
Real-world Effectiveness
16%
Assessment Period
16%
Past Failure
16%
Prospective Observation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Observational Study
100%
Transformed Migraine
100%
Erenumab
100%
Migraine
83%
Headache
33%
Adverse Event
33%
Clinical Trial
33%
Receptor
16%
Tolerability
16%
Calcitonin Gene Related Peptide
16%
Monoclonal Antibody
16%
Constipation
16%